The decoding of the human genome came with the promise of important biological insights that would ultimately help researchers eliminate many human diseases, including cancer. However, there are many steps to complete before scientists can directly link genetic information to a cure.
BCRF efforts in personalized medicine range from advancing our knowledge of tumor biology with the goal of creating targeted clinical interventions, to examining why one population with common ancestry has higher incidences of breast cancer than another, and finally to teasing out the genetic basis, if any, of why one individual benefits more from a specific drug or therapy than another. There is much to do but there is also much to look forward to in our ability to personalize, or individualize, medicine. We are proud that BCRF investigators are leading the way for the entire breast cancer community.
Investigations in 2012-2013 that are leading the Path towards Personalized Medicine are:
Fabrice Andr&eactue;, MD, PhD
Alan Ashworth, BSc, PhD, FRS
Lewis C. Cantley, PhD, Charles L. Sawyers, MD, and Gerburg Wulf, MD, PhD
Nancy E. Davidson, MD
Angelo Di Leo, MD, PhD
Heide L. Ford, PhD
Monica N. Fornier, MD and Angelo Di Leo, MD, PhD
Judy E. Garber, MD, MPH
Lyndsay N. Harris, MD
Daniel F. Hayes, MD and James M. Rae, PhD
James N. Ingle, MD
William G. Kaelin, Jr., MD
Joshua LaBaer, PhD
Rosette Lidereau, PhD
Steffi Oesterreich, PhD
C. Kent Osborne, MD and Rachel Schiff, PhD
Edith A. Perez, MD
Martine J. Piccart-Gebhart, MD, PhD
Kornelia Polyak, MD, PhD
Sir Bruce Ponder, MB, PhD and Christina Curtis, PhD
Lajos Pusztai, MD
Neal Rosen, MD, PhD
Christos Sotiriou, MD, PhD
Geoffrey M. Wahl, PhD
Max Wicha, MD
